1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
626AFB1F7CCA584A20025863900482464
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/26AFB1F7CCA584A20025863900482464?OpenDocument
18
19OpenDocument
2035.170.64.36
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Digital Technology » Cross-Functional Digital Transformation

Pharma’s Digital Transformation Turning Point for Medical and Commercial Leaders: Digital Implementation and Change in KPIs

ID: 5653


Features:

20 Info Graphics

11 Data Graphics

90+ Metrics

20 Narratives


Pages/Slides: 40


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Pharma’s Digital Transformation Turning Point for Medical and Commercial Leaders: Digital Implementation and Change in KPIs”

STUDY OVERVIEW

While the biopharma industry has been relatively slow in embracing innovative digital strategies, the global COVID-19 pandemic has brought about the much-needed digital transformation of the industry.

In the struggle to adapt, many companies have accelerated their adoption of digital solutions, not only to meet the pressing challenges but also to reimagine the business to better support healthcare stakeholders for years to come.

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies to uncover the most critical digital transformation strategies and programs being initiated across medical and commercial operational fronts in response to the COVID-19 pandemic. It spotlights key challenges and recommendations for biopharma leaders seeking to maximize performance and aid the digital growth of their own organization.

KEY TOPICS

  • Digital transformation of pharma medical and commercial strategies
  • Digital budget investment trends
  • Adapting to the virtual environment in COVID-19
  • Digital communicative and collaborative platforms
  • Digital transformation of key performance indicators

KEY METRICS
  • Due to the global pandemic, has your company implemented a limitation on face-to-face engagement with any of the listed external groups and which type of policy is reflected with each?
  • To what extent do you feel that the global pandemic will accelerate a trend towards digital external interactions at your company?
  • How have your investment patterns changed in response to the COVID-19 pandemic?
  • Due to the emergence of the global pandemic, what digital communicative and collaborative platforms are you currently implementing to add tactical functionality?
  • What tools or resources would you need to execute your role better during the global COVID-19 pandemic?
  • How have your company’s operations in implementing technology platforms changed because of the COVID-19 crisis?
  • Please rate the effectiveness of the listed parameters to provide incentives and compensation to field teams during the COVID-19 pandemic
  • What struggles have you experienced already or expect to see around performance measurement during the global pandemic?
  • What suggestions do you have for best adapting KPIs and other measurements during the global pandemic to better reflect performance?

SAMPLE KEY FINDINGS
  • New KPIs to reflect digital engagement model: Virtual interaction & channel effectiveness, sale process, skills development, and project assessment. KPIs still evolving.

METHODOLOGY

This Best Practices, LLC compendium draws upon 10 of our primary benchmark studies of over 200 biopharma executives from 178 life sciences companies to reveal the most effective digital strategies, tools and approaches being implemented by forward-looking Medical and Commercial leaders.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device; Biopharmaceutical; Laboratories; Clinical Research; Manufacturing; Consumer Products; Consulting; Technology; Communications; Computer Software; Telecommunications; Research; Medical; Professional Services; Science; Marketing


Companies Profiled:
Abbott; AbbVie; ADC Therapeutics; Advanced Accelerator Applications; AeroGen; Inc.; Agios; Aimmune Therapeutics; Alcon Laboratories; Align Technology; Alkem; Alkermes; Allergan; Almirall; Alnylam Pharmaceuticals; AMAG Pharmaceuticals; Amgen; Amicus Therapeutics; Apellis Pharmaceuticals; Aptus Clinical; Arena Pharmaceuticals; Ascend Therapeutics; Ascensia; Asklepion Pharmaceuticals; LLC; Aspen Pharmacare; Astellas; AstraZeneca; Atara Biotherapeutics; Avadel Pharmaceuticals; Avanir; Avant Healthcare; Avantor Performance Materials; Baxter Healthcare; Bayer; BioDelivery Sciences International; Biofrontera; Biogen; Boehringer Ingelheim; Bracco Diagnostics Inc.; Braeburn; B. Braun; Canopy Growth; Cara Therapeutics; Cascadia Drug Development Group; Catalyst Pharma; Celyad; Chiesi; Cipla; Cofactor Group; Consensus Orthopedics; CSL Behring; Daiichi Sankyo; DBV Tehcnologies; Deciphera Pharmaceuticals; Dendreon Pharmaceuticals LLC; DiaSorin; Eagle Pharmaceuticals; EHOB; Inc; Eisai; EMD Serono; eNeura Therapeutics; Ethypharm; EyePoint Pharmaceuticals; FerGene; Ferozsons Laboratories Limited; Ferring Pharmaceuticals; Frankel Advisory Group LLC; Galderma; GE Healthcare; Genmab; Getz Pharma; Greenwich Biosciences; Grifols; Grünenthal; Guerbet; Halloran Consulting Group; Helsinn; Horizon Therapeutics; IDbyDNA; Idorsia; Ipsen; Iridex; Ironwood; Joerns Healthcare; Johnson & Johnson; Kala Pharmaceuticals; Kaleo; Karyopharm Therapeutics; Kiniksa Pharmaceuticals; Kyowa Kirin; Leica Biosystems; LeMaitre Vascular; LEO Pharma; Lundbeck; Lupin; Mayne Pharma; Medacta USA; Medexus Pharmaceuticals; Medicure; MedinCell; MEDiSTRAVA; Medrobotics; Medtronic; Melinta Therapeutics; Merck; Merck KGaA; Milestone Pharmaceuticals; Mint Pharmaceuticals Inc.; Mirador Global LP; Mission Bio; Monebo Technologies; Nabriva Therapeutics; Nestle Health Science; Nevakar; NexGen Healthcare Communications; Nobio; Novartis; Novo Nordisk; Nuvisan; Ora; Osmotica Pharmaceuticals; OTSUKA; Panacea Biotec; Paratek Pharmaceuticals; Pfizer; Piramal Group; Prime Global; Proteus Digital Health; Purdue Pharma; QED Therapeutics; Retrophin; Rigel Pharmaceuticals; Roche; Samumed; Sandoz; Sanofi; Sanofi Genzyme; Sanofi Pasteur; Santen; Santhera Pharmaceuticals; Sarah Cannon; Scilex Pharmaceuticals; Servier; Shionogi Inc.; Sivantos Pte. Ltd.; SK Life Science; Smith & Nephew; SomaGenics Inc; Stgilesmedical London & Berlin; Straumann; Sumitovant BioPharma; Sunovion; Supernus; Surrozen; Syneos Health; Takeda Pharmaceuticals; Tecan; TerSera Therapeutics; TG Therapeutics; The Medical Affairs Company; The Stem; Theravance; Thermo Fisher Scientific; Think Surgical; Thompson Surgical Instruments; UCB Pharma; United BioSource; Vertex Pharmaceuticals; Vifor Pharma; ViiV Healthcare; Visioneering Technologies Inc.; Wellspect HealthCare; West 53rd St Digital; Worldwide Clinical Trials; XACT Robotics; XG Sciences; Zeiss Pharma; Zosano Pharma; Zydus Cadila

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.